REAL-WORLD UTILIZATION OF TALAZOPARIB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN THE UNITED STATES
Author(s)
Suvina Amin, BSc, MPH1, Shel Liang, PhD1, Melissa Kirker, PharmD MPH2, Neo Su, MPH, MS, PharmD3, Samuel Wagner, PhD4, Onur Baser5, Katarzyna Rodchenko, MA, MPH6, Shuangrui Chen, MS6, Precious Nchekwube, MPH6, Lixuan Wu7, Sarah Hanson, MD, PhD, MBA1.
1Pfizer, New York, NY, USA, 2Pfizer, Washington, DC, USA, 3Pfizer, Houston, TX, USA, 4Columbia Data Analytics, Newtown, PA, USA, 5New York, NY, USA, 6Columbia Data Analytics, New York, NY, USA, 7USA.
1Pfizer, New York, NY, USA, 2Pfizer, Washington, DC, USA, 3Pfizer, Houston, TX, USA, 4Columbia Data Analytics, Newtown, PA, USA, 5New York, NY, USA, 6Columbia Data Analytics, New York, NY, USA, 7USA.
OBJECTIVES: Talazoparib plus enzalutamide (tala+enza) was approved in the United States in June 2023 for homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer (mCRPC). Claim-based evidence describing early uptake and treatment history remains limited. We described early real-world use of tala+enza among initiating patients.
METHODS: This retrospective cohort study used de-identified US claims from the Kythera Labs. Men with metastatic prostate cancer (mPC) initiating tala+enza between June 20, 2023, and August 31, 2025, were included. Combination therapy was defined as initiation of the second agent within 90 days of the first; the index date was the second agent’s start date. Because castration resistance cannot be directly confirmed in claims, tala+enza initiation was used as a claims-based proxy for treatment in the mCRPC setting. Patients had ≥36 months of continuous enrollment pre-index. Descriptive analyses assessed demographics, socioeconomic status (SES), comorbidity, prior therapies, treatment setting, and prescriber specialty.
RESULTS: Overall, 226 men met eligibility criteria. Mean age was 74.0 years, and mean Charlson Comorbidity Index score was 2.54. Common comorbidities included hypertension (48.2%) and diabetes (22.6%). SES was balanced across tertiles: high 33.2%, low 32.3%, middle 31.9%. During the 36-month pre-index period, 65.5% received an androgen receptor pathway inhibitor, 48.7% any androgen deprivation therapy, and 21.7% chemotherapy. Most patients initiated both agents on the same date (70.4%) and started talazoparib at 0.5 mg (79.6%). Median follow-up time was 366 days. Treatment was predominantly captured within community practices (80.5%), reflecting Kythera’s provider-network composition; oncology specialists were the primary treating providers (90.8%).
CONCLUSIONS: In this early US claims-based analysis, tala+enza was initiated among men with mCRPC, many of whom had prior exposure to commonly used mPC therapies. Most patients initiated both agents concurrently, and treatment was primarily managed by oncologists in community settings. These findings provide early insights into real-world uptake of tala+enza in routine oncology practice.
METHODS: This retrospective cohort study used de-identified US claims from the Kythera Labs. Men with metastatic prostate cancer (mPC) initiating tala+enza between June 20, 2023, and August 31, 2025, were included. Combination therapy was defined as initiation of the second agent within 90 days of the first; the index date was the second agent’s start date. Because castration resistance cannot be directly confirmed in claims, tala+enza initiation was used as a claims-based proxy for treatment in the mCRPC setting. Patients had ≥36 months of continuous enrollment pre-index. Descriptive analyses assessed demographics, socioeconomic status (SES), comorbidity, prior therapies, treatment setting, and prescriber specialty.
RESULTS: Overall, 226 men met eligibility criteria. Mean age was 74.0 years, and mean Charlson Comorbidity Index score was 2.54. Common comorbidities included hypertension (48.2%) and diabetes (22.6%). SES was balanced across tertiles: high 33.2%, low 32.3%, middle 31.9%. During the 36-month pre-index period, 65.5% received an androgen receptor pathway inhibitor, 48.7% any androgen deprivation therapy, and 21.7% chemotherapy. Most patients initiated both agents on the same date (70.4%) and started talazoparib at 0.5 mg (79.6%). Median follow-up time was 366 days. Treatment was predominantly captured within community practices (80.5%), reflecting Kythera’s provider-network composition; oncology specialists were the primary treating providers (90.8%).
CONCLUSIONS: In this early US claims-based analysis, tala+enza was initiated among men with mCRPC, many of whom had prior exposure to commonly used mPC therapies. Most patients initiated both agents concurrently, and treatment was primarily managed by oncologists in community settings. These findings provide early insights into real-world uptake of tala+enza in routine oncology practice.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
RWD58
Topic
Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
Oncology